The adverse reactions of piperacillin: a systematic review_Chinese Journal of Evidence-Based Medicine

Authors：

ZHANG Hongru ^1,2 ,  YANG Liping ¹

1. Department of Pharmacy, Beijing Hospital; National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences; Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, P. R. China;
2. Department of Pharmacy, The First Hospital of Zhangjiakou, Zhangjiakou 075000, P. R. China;

Corresponding?author：

YANG Liping, Email: yanglp-2000@hotmail.com

Keywords：

Piperacillin; Adverse drug reactions; Case reports; Systematic review

DOI：

10.7507/1672-2531.202208061

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the adverse drug reactions (ADRs) caused by piperacillin. Methods PubMed, EMbase, Web of Science, CNKI, WanFang Data and VIP databases were electronically searched to collect case reports on ADRs caused by piperacillin from inception to December 31, 2021. Two reviewers independently screened literature, extracted data and then a qualitative systematic review was performed. Results A total of 168 case reports involving 170 patients were included. The male to female ratio was 1.06∶1, and the median age was 54 year old. The statistical results showed that ADRs caused by piperacillin mostly involved the whole body (n=55), followed by the blood system (n=48), skin and soft tissue system (n=39) and nervous system (n=18). The most frequently reported cases were anaphylactic shock (n=29), followed by drug fever (n=19), rash (n=17) and thrombocytopenia (n=15). The most serious ADRs were anaphylactic shock (n=29) and bullous epidermal necrolysis (n=6). Conclusion Current evidence shows that ADRs caused by piperacillin mostly involved the whole body and the most serious ADRs are toxic epidermal necrolysis and anaphylactic shock.

Citation： ZHANG Hongru, YANG Liping. The adverse reactions of piperacillin: a systematic review. Chinese Journal of Evidence-Based Medicine, 2023, 23(2): 191-196. doi: 10.7507/1672-2531.202208061 Copy

1.	Gaspar-Marques J, Finelli E, Martins PC, et al. Piperacillin-tazobactam anaphylaxis: a rare cause of occupational disease. Eur Ann Allergy Clin Immunol, 2018, 50(2): 89-91.
2.	Bassetti M, Giacobbe DR, Robba C, et al. Treatment of extended-spectrum β-lactamases infections: what is the current role of new β-lactams/β-lactamase inhibitors. Curr Opin Infect Dis, 2020, 33(6): 474-481.
3.	Wang Q, He Z, Wu X, et al. Hematologic adverse effects induced by piperacillin-tazobactam: a systematic review of case reports. Int J Clin Pharm, 2020, 42(4): 1026-1035.
4.	Kim TI, Jeong KH, Shin MK, et al. Piperacillin/tazobactam-associated hypersensitivity syndrome with overlapping features of acute generalized exanthematous pustulosis and drug-related rash with eosinophilia and systemic symptoms syndrome. Ann Dermatol, 2016, 28(1): 98-101.
5.	Gallardo A, Moreno EM, Laffond E, et al. Sensitization phenotypes in immediate reactions to piperacillin-tazobactam. J Allergy Clin Immunol Pract, 2020, 8(9): 3175-3177.
6.	Wong JC, Au EY, Yeung HH, et al. Piperacillin-tazobactam allergies: an exception to usual penicillin allergy. Allergy Asthma Immunol Res, 2021, 13(2): 284-294.
7.	Poggiali E, Benedetti I, Vertemati V, et al. Kounis syndrome: from an unexpected case in the Emergency Room to a review of the literature. Acta Biomed, 2022, 93(1): e2022002.
8.	Rico Cepeda P, Palencia Herrejón E, Rodríguez Aguirregabiria MM. Kounis syndrome. Med Intensiva, 2012, 36(5): 358-364.
9.	Alblaihed L, Huis In 't Veld MA. Allergic acute coronary syndrome-Kounis syndrome. Emerg Med Clin North Am, 2022, 40(1): 69-78.
10.	Sciatti E, Vizzardi E, Cani DS, et al. Kounis syndrome, a disease to know: Case report and review of the literature. Monaldi Arch Chest Dis, 2018, 88(1): 898.
11.	Calogiuri GF, Nettis E, Di Leo E, et al. Kounis Syndrome induced by intravenous administration of piperacillin/tazobactam: a case report. Int J Cardiol, 2012, 155(3): e42-44.
12.	Yamashita T, Oguma Y, Kounis NG. Kounis syndrome: kill two birds with one stone. J Invasive Cardiol, 2021, 33(11): E920-E921.
13.	Chow KM, Hui AC, Szeto CC. Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis, 2005, 24(10): 649-653.
14.	Rezaei NJ, Bazzazi AM, Naseri Alavi SA. Neurotoxicity of the antibiotics: A comprehensive study. Neurol India, 2018, 66(6): 1732-1740.
15.	Roger C, Louart B. Beta-lactams toxicity in the intensive care unit: an underestimated collateral damage. Microorganisms, 2021, 9(7): 1505.
16.	Man BL, Fu YP. Piperacillin/tazobactam-induced myoclonic jerks in a man with chronic renal failure. BMJ Case Rep, 2015, 2015: bcr2015210184.
17.	Mattappalil A, Mergenhagen KA. Neurotoxicity with antimicrobials in the elderly: a review. Clin Ther, 2014, 36(11): 1489-1511.
18.	黃雅群, 文睿婷, 于芝穎, 等. 哌拉西林及其復方制劑致過敏性休克的病例報道及文獻分析. 中國藥房, 2021, 32(1): 82-87.
19.	周法庭, 朱曉丹, 波順慶, 等. β-內酰胺環和側鏈結構誘導青霉素類抗生素過敏的研究進展. 醫學綜述, 2018, 24(3): 444-448.
20.	田力. 注射用哌拉西林鈉他唑巴坦鈉的含量測定及其配伍穩定性的考察. 大連醫科大學, 2011.
21.	胡麗, 黃琨, 俞仁濤. Stevens-Johnson綜合征和中毒性表皮壞死松解癥的疾病進展和治療轉歸分析. 中國皮膚性病學雜志, 2022, 36(3): 290-294.
22.	中華醫學會皮膚性病學分會藥物不良反應研究中心. Stevens-Johnson綜合征/中毒性表皮壞死松解癥診療專家共識. 中華皮膚科雜志, 2021, 54(5): 376-381.
23.	李希國, 謝嬌. 1例大皰性表皮松解壞死型藥疹患者的治療與探討. 中國醫藥指南, 2011, 9(8): 139.
24.	劉立立, 黃玲, 胡正波, 等. 哌拉西林鈉他唑巴坦鈉致大皰表皮松解型藥疹1例. 中國藥物警戒, 2013, 10(11): 703-704.
25.	吳翠芳. 哌拉西林他唑巴坦相關性大皰性表皮壞死松解癥1例. 南京: 2012年中國藥學大會暨第十二屆中國藥師周, 2012.

1. Gaspar-Marques J, Finelli E, Martins PC, et al. Piperacillin-tazobactam anaphylaxis: a rare cause of occupational disease. Eur Ann Allergy Clin Immunol, 2018, 50(2): 89-91.
2. Bassetti M, Giacobbe DR, Robba C, et al. Treatment of extended-spectrum β-lactamases infections: what is the current role of new β-lactams/β-lactamase inhibitors. Curr Opin Infect Dis, 2020, 33(6): 474-481.
3. Wang Q, He Z, Wu X, et al. Hematologic adverse effects induced by piperacillin-tazobactam: a systematic review of case reports. Int J Clin Pharm, 2020, 42(4): 1026-1035.
4. Kim TI, Jeong KH, Shin MK, et al. Piperacillin/tazobactam-associated hypersensitivity syndrome with overlapping features of acute generalized exanthematous pustulosis and drug-related rash with eosinophilia and systemic symptoms syndrome. Ann Dermatol, 2016, 28(1): 98-101.
5. Gallardo A, Moreno EM, Laffond E, et al. Sensitization phenotypes in immediate reactions to piperacillin-tazobactam. J Allergy Clin Immunol Pract, 2020, 8(9): 3175-3177.
6. Wong JC, Au EY, Yeung HH, et al. Piperacillin-tazobactam allergies: an exception to usual penicillin allergy. Allergy Asthma Immunol Res, 2021, 13(2): 284-294.
7. Poggiali E, Benedetti I, Vertemati V, et al. Kounis syndrome: from an unexpected case in the Emergency Room to a review of the literature. Acta Biomed, 2022, 93(1): e2022002.
8. Rico Cepeda P, Palencia Herrejón E, Rodríguez Aguirregabiria MM. Kounis syndrome. Med Intensiva, 2012, 36(5): 358-364.
9. Alblaihed L, Huis In 't Veld MA. Allergic acute coronary syndrome-Kounis syndrome. Emerg Med Clin North Am, 2022, 40(1): 69-78.
10. Sciatti E, Vizzardi E, Cani DS, et al. Kounis syndrome, a disease to know: Case report and review of the literature. Monaldi Arch Chest Dis, 2018, 88(1): 898.
11. Calogiuri GF, Nettis E, Di Leo E, et al. Kounis Syndrome induced by intravenous administration of piperacillin/tazobactam: a case report. Int J Cardiol, 2012, 155(3): e42-44.
12. Yamashita T, Oguma Y, Kounis NG. Kounis syndrome: kill two birds with one stone. J Invasive Cardiol, 2021, 33(11): E920-E921.
13. Chow KM, Hui AC, Szeto CC. Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis, 2005, 24(10): 649-653.
14. Rezaei NJ, Bazzazi AM, Naseri Alavi SA. Neurotoxicity of the antibiotics: A comprehensive study. Neurol India, 2018, 66(6): 1732-1740.
15. Roger C, Louart B. Beta-lactams toxicity in the intensive care unit: an underestimated collateral damage. Microorganisms, 2021, 9(7): 1505.
16. Man BL, Fu YP. Piperacillin/tazobactam-induced myoclonic jerks in a man with chronic renal failure. BMJ Case Rep, 2015, 2015: bcr2015210184.
17. Mattappalil A, Mergenhagen KA. Neurotoxicity with antimicrobials in the elderly: a review. Clin Ther, 2014, 36(11): 1489-1511.
18. 黃雅群, 文睿婷, 于芝穎, 等. 哌拉西林及其復方制劑致過敏性休克的病例報道及文獻分析. 中國藥房, 2021, 32(1): 82-87.
19. 周法庭, 朱曉丹, 波順慶, 等. β-內酰胺環和側鏈結構誘導青霉素類抗生素過敏的研究進展. 醫學綜述, 2018, 24(3): 444-448.
20. 田力. 注射用哌拉西林鈉他唑巴坦鈉的含量測定及其配伍穩定性的考察. 大連醫科大學, 2011.
21. 胡麗, 黃琨, 俞仁濤. Stevens-Johnson綜合征和中毒性表皮壞死松解癥的疾病進展和治療轉歸分析. 中國皮膚性病學雜志, 2022, 36(3): 290-294.
22. 中華醫學會皮膚性病學分會藥物不良反應研究中心. Stevens-Johnson綜合征/中毒性表皮壞死松解癥診療專家共識. 中華皮膚科雜志, 2021, 54(5): 376-381.
23. 李希國, 謝嬌. 1例大皰性表皮松解壞死型藥疹患者的治療與探討. 中國醫藥指南, 2011, 9(8): 139.
24. 劉立立, 黃玲, 胡正波, 等. 哌拉西林鈉他唑巴坦鈉致大皰表皮松解型藥疹1例. 中國藥物警戒, 2013, 10(11): 703-704.
25. 吳翠芳. 哌拉西林他唑巴坦相關性大皰性表皮壞死松解癥1例. 南京: 2012年中國藥學大會暨第十二屆中國藥師周, 2012.

Chinese Journal of Evidence-Based Medicine

The adverse reactions of piperacillin: a systematic review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content